Drugs / Glycyrrhetic Acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT00759525 Comparator | Feb 2002 → Sep 2009 | apparent mineralocorticoid excess | Brigham and Women's Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glycyrrhetic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00759525 ↗ |
| Known as | glycyrrhetinic acid | “A total of 15 healthy subjects were treated with the selective 11beta-HSD inhibitor GA (glycyrrhetinic acid) or matching placebo in a randomized double-blinded cross-over trial.” PMID 20515440 ↗ Aug 2010 |